Speciality: Oncology
Description:
In this insightful presentation, renowned oncologist Dr. Nagender Sharma delves into the evolving landscape of advanced urothelial carcinoma treatment. With a focus on evidence-based strategies, Dr. Sharma welcomes viewers to explore the latest advancements, clinical trial insights, and personalized approaches that are reshaping patient care. He emphasizes the importance of integrating immunotherapy, targeted therapies, and chemotherapy while addressing challenges like resistance mechanisms and biomarker-driven decision-making. This video serves as a comprehensive guide for clinicians seeking to optimize outcomes in this complex malignancy.
Dr. Sharma meticulously examines cutting-edge therapies such as immune checkpoint inhibitors, antibody-drug conjugates (e.g., enfortumab vedotin), and FGFR inhibitors, highlighting their roles in first-line and subsequent treatments. He discusses real-world applications of combination regimens, patient selection criteria, and the impact of molecular profiling on tailoring therapies. Additionally, he sheds light on emerging trends, including adaptive clinical trial designs and the potential of novel biomarkers to refine prognostic accuracy. His analysis balances optimism with pragmatism, acknowledging hurdles like toxicity management and access disparities.
Concluding with a forward-looking perspective, Dr. Nagender Sharma underscores the collaborative effort required to translate scientific breakthroughs into tangible survival benefits for patients. Viewers are encouraged to watch the full video to gain actionable insights and stay abreast of this rapidly advancing field. Don’t miss this opportunity to learn from a leading expert. Subscribe for future updates and deepen your understanding of oncology’s most pressing challenges.
See More Webinars @ Hidoc Webinars
1.
Nearly 6 Million Deaths From Five Major Cancer Types Averted Since 1975
2.
Child Death Rates Are Rising in the U. s. ; Water Beads Warning; Cancer Studies Retracted.
3.
Interleukin-6 may boost prediction of obesity-related cancers
4.
Researchers use AI to monitor side effects of chemotherapy and support families dealing with pediatric cancer.
5.
As EGFR internalization is decreased, BUB1 controls EGFR signaling.
1.
HPV-Related Cervical Cancer: Advances in Screening, Preventiofn & Treatment
2.
Cancer Diagnosis in 2025: Innovations, Education, and Evolving Clinical Strategies
3.
HCC Codes in Oncology: Care Optimization in Plexiform Neurofibroma Management
4.
Unraveling the Mysteries of Coagulopathy: A Comprehensive Definition
5.
Unlocking the Mystery of Methaemoglobinaemia: A New Hope for Treatment
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part IV
2.
An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Q & A Session
3.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia
4.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC
5.
Exploring the Hospitalization Burden in Refractory and Relapsed ALL
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation